PD42-01 RESIDUAL MUSCLE-INVASIVE DISEASE AT CYSTECTOMY IS NOT ACCURATELY PREDICTED BY POST-CHEMOTHERAPY RESTAGING PROTOCOLS INCLUDING DNA DAMAGE RESPONSE GENE MUTATION ANALYSIS
2020
INTRODUCTION AND OBJECTIVE:The standard of care for eligible patients with muscle-invasive bladder cancer (MIBC) includes neoadjuvant cisplatin-based chemotherapy (NAC), followed by radical cystect...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI